Clinical Trials in San Diego

Showing 1201-1220 of 14,679 trials

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

NCT04634916

A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.

Kidney Disease, End-StageEnd-stage Renal DiseaseArteriovenous Fistula

C. R. Bard280 participantsStarted Mar 2021

La Jolla, California, United States • San Francisco, California, United States • Jacksonville, Florida, United States +14 more locations

RECRUITINGPhase 311 miles

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more

Genelux Corporation186 participantsStarted Aug 2022

Mobile, Alabama, United States • Tucson, Arizona, United States • Duarte, California, United States +28 more locations

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Find Trials by Condition in San Diego

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

An Open Label Study of CM-AT for the Treatment of Children With Autism

A Study of DF6002 Alone and in Combination With Nivolumab

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Venclose digiRF System Post Market Study

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP